Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Zeiser

Showing results (111-120 of 373) with videos related to

Pageof 38
Sort By:
Immunotherapy|January 11, 2018
Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH  trialsMadan Jagasia, Robert Zeiser, Michael Arbushites, et al.
Bone Marrow Transplantation|April 16, 2025
Regulatory T cell therapy for Graft-versus-Host DiseaseMemnon Lysandrou, Dionysia Kefala, Janaki Manoja Vinnakota, et al.
Blood|September 11, 2007
Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activityRobert Zeiser, Sawsan Youssef, Jeanette Baker, et al.
Immunology|February 5, 2009
Regulation of different inflammatory diseases by impacting the mevalonate pathwayRobert Zeiser, Kristina Maas, Sawsan Youssef, et al.
Scientific Reports|December 13, 2017
Negative regulation of TGF-β1-induced MKK6-p38 and MEK-ERK signalling and epithelial-mesenchymal transition by Rac1bDavid Witte, Hannah Otterbein, Maria Förster, et al.
Bone Marrow Transplantation|June 29, 2022
Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tractFrancesca Biavasco, Gabriele Ihorst, Ralph Wäsch, et al.
Biorxiv : the Preprint Server for Biology|June 22, 2026
Spatial Transcriptomics reveals a T cell-mediated microglial activation axis of neurodegeneration following immune checkpoint inhibitionDevyani Swami, Suhas Sureshchandra, Janaki Manoja Vinnakota, et al.
Annals of Hematology|September 24, 2024
15-year remission in refractory FLT3-mutated AML attained by sorafenibChristoph Rummelt, Dietmar Pfeifer, Ralph Wäsch, et al.
European Journal of Immunology|February 18, 2025
Towards the Next Generation of Data-Driven Therapeutics Using Spatially Resolved Single-Cell Technologies and Generative AIAvital Rodov, Hosna Baniadam, Robert Zeiser, et al.
Blood Advances|June 5, 2025
Impact of concomitant azoles on ruxolitinib treatment in patients with GVHD: post hoc analyses of REACH2 and REACH3Zahra Mahmoudjafari, Emily Kintsch, Zhenyi Xue, et al.
Pageof 38

Showing results (111-120 of 373) with videos related to

Sort By:
Pageof 38
Immunotherapy|January 11, 2018
Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH  trialsMadan Jagasia, Robert Zeiser, Michael Arbushites, et al.
Bone Marrow Transplantation|April 16, 2025
Regulatory T cell therapy for Graft-versus-Host DiseaseMemnon Lysandrou, Dionysia Kefala, Janaki Manoja Vinnakota, et al.
Blood|September 11, 2007
Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activityRobert Zeiser, Sawsan Youssef, Jeanette Baker, et al.
Immunology|February 5, 2009
Regulation of different inflammatory diseases by impacting the mevalonate pathwayRobert Zeiser, Kristina Maas, Sawsan Youssef, et al.
Scientific Reports|December 13, 2017
Negative regulation of TGF-β1-induced MKK6-p38 and MEK-ERK signalling and epithelial-mesenchymal transition by Rac1bDavid Witte, Hannah Otterbein, Maria Förster, et al.
Bone Marrow Transplantation|June 29, 2022
Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tractFrancesca Biavasco, Gabriele Ihorst, Ralph Wäsch, et al.
Biorxiv : the Preprint Server for Biology|June 22, 2026
Spatial Transcriptomics reveals a T cell-mediated microglial activation axis of neurodegeneration following immune checkpoint inhibitionDevyani Swami, Suhas Sureshchandra, Janaki Manoja Vinnakota, et al.
Annals of Hematology|September 24, 2024
15-year remission in refractory FLT3-mutated AML attained by sorafenibChristoph Rummelt, Dietmar Pfeifer, Ralph Wäsch, et al.
European Journal of Immunology|February 18, 2025
Towards the Next Generation of Data-Driven Therapeutics Using Spatially Resolved Single-Cell Technologies and Generative AIAvital Rodov, Hosna Baniadam, Robert Zeiser, et al.
Blood Advances|June 5, 2025
Impact of concomitant azoles on ruxolitinib treatment in patients with GVHD: post hoc analyses of REACH2 and REACH3Zahra Mahmoudjafari, Emily Kintsch, Zhenyi Xue, et al.
Pageof 38